GSK’s Promising Update: Belantamab Mafodotin and Nirogacestat in RRMM Study

GlaxoSmithKline ((GSK)), GlaxoSmithKline plc (UK) ((GB:GSK)) announced an update on their ongoing clinical study.

Study Overview: GlaxoSmithKline is conducting a Phase I/II study titled ‘A Phase I/II, Randomized, Open-label Platform Study Utilizing a Master Protocol to Study Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Anti-Cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)-DREAMM5 – Sub-study 3 – Belantamab Mafodotin and Nirogacestat in Combination.’ The study aims to assess the safety and tolerability of belantamab mafodotin combined with nirogacestat in patients with relapsed/refractory multiple myeloma, with the goal of establishing a recommended Phase 2 dose.

Intervention/Treatment: The study tests the combination of two drugs: Belantamab mafodotin and Nirogacestat. Belantamab mafodotin is an anti-cancer drug, while Nirogacestat is intended to enhance its effects. Together, they aim to improve treatment outcomes for multiple myeloma patients.

Study Design: This interventional study follows a single-group assignment model with no masking, focusing primarily on treatment. Participants receive the experimental combination of belantamab mafodotin and nirogacestat to evaluate its effects.

Study Timeline: The study began on June 8, 2020. As of the last update on July 22, 2025, the study is active but not recruiting new participants. These dates are crucial for tracking the study’s progress and anticipating future updates.

Market Implications: This study update could influence GSK’s stock performance by signaling potential advancements in cancer treatment, which may boost investor confidence. The combination therapy’s success could position GSK favorably against competitors in the oncology market, potentially impacting market dynamics.

The study is ongoing, with further details available on the ClinicalTrials portal.